Additionally, fostamatinib, a spleen tyrosine kinase inhibitor that is licensed in chronic immune thrombocytopenia and has successfully completed phase 3 clinical trials for treating rheumatoid arthritis, is among the repurposed candidate drugs. This evidence concerns the gene SYK and rheumatoid arthritis.